Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
Note: The archived version of this monograph has been temporarily removed. For an electronic copy of this archived version, please contact the Natural Health Products Directorate (NHPD) at NHPD_DPSN@hc-sc.gc.ca.
Date: November 8, 2007
Proper name(s): Vitamin B12 (Sweetman 2007; IOM 2003; O'Neil et al. 2001)
Common name(s): Cyanocobalamin, vitamin B12 (Sweetman 2007; IOM 2003; O'Neil et al. 2001)
Source material(s):
Note: The slash (/) indicates that the terms are synonyms. Either term may be selected by the applicant.
Route(s) of administration: Oral
Dosage form(s): Those pharmaceutical dosage forms suited to oral administration, including but not limited to chewable tablets, caplets, capsules, strips, lozenges, powders or liquids where the dose is measured in drops, teaspoons, or tablespoons are acceptable. This monograph is not intended to include food-like dosage forms such as bars, chewing gums or beverages.
Use(s) or Purpose(s): Statement(s) to the effect of:
General claim: A factor in the maintenance of good health (IOM 2006; IOM 1998).
Specific claims:
Dose-specific claim: For products providing daily doses of vitamin B12 at or above the Recommended Dietary Allowance (RDA) (adjusted for the life stage groups), the following use or purpose is acceptable:
Helps to prevent vitamin B12 deficiency (IOM 2006; Shils et al. 2006; Groff and Gropper 2000; IOM 1998).
See Appendix 1 for definitions and Table 2 in Appendix 2 for AI values.
Dose(s):
Table 1: Dose information for vitamin B12 presented as dose per day
| Life stage group | Vitamin B12 (μg/day) | ||
|---|---|---|---|
| Minimum1 | Maximum2 | ||
| Children | 1-3 y | 0.9 | 1,000 |
| 4-8 y | 0.9 | 1,000 | |
| Adolescents | 9-13 y | 0.9 | 1,000 |
| 14-18 y | 0.14 | 1,000 | |
| Adults3 | ≥ 19 y | 0.14 | 1,000 |
1 Based on approximately 5% of the highest RDA (IOM 2006). See Appendix 1 for definitions and Table 2 in Appendix 2 for RDA values.
2 Maximum dose supported by the following references: HC 2006 and FSA 2003.
3 Includes pregnant and breastfeeding women.
Duration of use: No statement required.
Risk information: Statement(s) to the effect of:
Caution(s) and warning(s): No statement required.
Contraindication(s): No statement required.
Known adverse reaction(s): No statement required.
Non-medicinal ingredients: Must be chosen from the current NHPD List of Acceptable Non-medicinal Ingredients and must meet the limitation outlined in the list.
Specifications: Must comply with the minimum specifications outlined in the current NHPD Compendium of Monographs.
References:
Chalmers RA, Bain MD, Costello I. Oral cobalamin therapy. Lancet 2000;355(9198):148.
EC 2000: European Commission. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake level of Vitamin B12. Brussels (BE): European Commission, SCF/CS/NUT/UPPLEV/42 Final 28 November 2000. [Accessed 2007-09-26]. Available from: http://ec.europa.eu/food/fs/sc/scf/out80_en.html.
FSA 2003: Food Standards Agency. Expert Group on Vitamins and Minerals. Risk Assessment: Vitamin B12. London (UK): Food Standards Agency, Expert Group on Vitamins and Minerals 2003. [Accessed 2007-06-04] Available at: www.food.gov.uk/multimedia/pdfs/evm_b12.pdf
Groff J, Gropper S. Advanced Nutrition and Human Metabolism, 3rd edition. Belmont (CA): Wadsworth/Thomson Learning; 2000.
HC 2006: Health Canada. NHPD Expert Advisory Committee Issue Analysis Summary: What is an appropriate maximum daily dose for vitamin B12? Ottawa (ON): Natural Health Products Directorate, Health Canada; 2006.
IOM 2006: Institute of Medicine. Otten JJ, Pitzi Hellwig J, Meyers LD, editors. Institute of Medicine Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington (DC): National Academy Press; 2006.
IOM 2003: Institute of Medicine. Committee on Food Chemicals Codex, Food and Nutrition Board, Institute of Medicine. Food Chemicals Codex, 5th edition. Washington (DC): National Academies Press; 2003.
IOM 1998: Institute of Medicine. Panel on Folate, other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. Washington (DC): National Academy Press; 1998.
O'Neil MJ, Smith A, Heckelman PE, Budavari S, editors. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th edition. Whitehouse Station (NJ): Merck & Co., Inc; 2001.
Shils ME, Olson JA, Shike M, Ross AC, editors. Modern Nutrition in Health and Disease, 10th edition. Philadelphia (PA): Lippincott Williams and Wilkins; 2006.
Sweetman SC, editor. Martindale: The Complete Drug Reference, 35th edition. London (UK): Pharmaceutical Press; 2007.
Van Der Kuy PH, Merkus FW, Lohman JJ, Ter Berg JW, Hooymans PM. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia 2002;22(7):513-519.
Yamagata S, Goto Y, Mita M, Kikuchi J, Yamauchi Y. Treatment of diabetic neuropathy with the oral administration of hydroxocobalamin. Vitamins 1966;34(3):349-356.
Zeitlin HC, Sheppard K, Baum JD, Bolton FG, Hall CA. Homozygous transcobalamin II deficiency maintained on oral hydroxocobalamin. Blood 1985;66(5):1022-1027.
Appendix 1: Definitions
Recommended Dietary Allowances (RDA): The average daily dietary nutrient intake level sufficient to meet the nutrient requirements of nearly all (97-98%) healthy individuals in a particular life stage and gender group (IOM 2006).
Appendix 2: RDA Values
The RDA values for vitamin B12 are provided below. For the purpose of this monograph, these values are intended to:
Table 2: Recommended Dietary Allowance values for vitamin B12 based on life stage group (IOM 2006)
| Life stage group | Vitamin B12 (μg/day) | |
|---|---|---|
| Children | 1-3 y | 0.9 |
| 4-8 y | 1.2 | |
| Adolescents | 9-13 y | 1.8 |
| 14-18 y | 2.4 | |
| Adults | ≥ 19 y | 2.4 |
| Pregnancy | 14-50 y | 2.6 |
| Breastfeeding | 14-50 y | 2.8 |